Advertisement

Congenital Factor VII Deficiency

  • Mahmood Shams
  • Akbar Dorgalaleh
Chapter
First Online:

Abstract

Congenital factor VII (FVII) deficiency with a prevalence of 1 per 500,000 is the most common rare bleeding disorder. Although the majority of patients have mild bleeding tendency, a considerable number of them present life-threatening bleedings such as central nervous system (CNS) and gastrointestinal (GI) bleedings. Although the diagnosis of congenital FVII deficiency is straightforward with isolated prolonged prothrombin time (PT) and decreased FVII level, differential diagnosis of acquired FVII deficiency should be considered. Several therapeutic options such as fresh frozen plasma (FFP), plasma-derived FVII (pd-FVII), prothrombin complex concentrate (PCC), activated PCC (aPCC), and, more recently, recombinant activated FVII (rFVIIa) are available for treatment of patients with FVII deficiency. New therapeutic options significantly improved the quality of life in patients with congenital FVII deficiency.

Keyword

Factor VII deficiency Rare bleeding disorder Clinical manifestations Diagnosis Treatment 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Sevenet P-O, Kaczor DA, Depasse F. Factor VII deficiency: from basics to clinical laboratory diagnosis and patient management. Clin Appl Thromb Hemost. 2016.  https://doi.org/10.1177/1076029616670257.
  2. 2.
    Herrmann F, Wulff K, Auerswald G, Schulman S, Astermark J, Batorova A, et al. Factor VII deficiency: clinical manifestation of 717 subjects from Europe and Latin America with mutations in the factor 7 gene. Haemophilia. 2009;15(1):267–80.CrossRefPubMedGoogle Scholar
  3. 3.
    Perry DJ. Factor VII deficiency. Br J Haematol. 2002;118(3):689–700.CrossRefPubMedGoogle Scholar
  4. 4.
    Lapecorella M, Mariani G. Factor VII deficiency: defining the clinical picture and optimizing therapeutic options. Haemophilia. 2008;14(6):1170–5.CrossRefPubMedGoogle Scholar
  5. 5.
    Peyvandi F, James P, Salomon O, Mikovic D. Rare bleeding disorders. Haemophilia. 2014;20(4):71.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Mariani G, Herrmann FH, Dolce A, Batorova A, Etro D, Peyvandi F, et al. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost. 2005;93(3):481.PubMedGoogle Scholar
  7. 7.
    Mackman N. The role of tissue factor and factor VIIa in hemostasis. Anesth Analg. 2009;108(5):1447.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Rosen ED, Chan JC, Idusogie E, Clotman F. Mice lacking factor VII develop normally but suffer fatal perinatal bleeding. Nature. 1997;390(6657):290.CrossRefPubMedGoogle Scholar
  9. 9.
    Moerloose P, Schved JF, Nugent D. Rare coagulation disorders: fibrinogen, factor VII and factor XIII. Haemophilia. 2016;22(S5):61–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Smith SA, Travers RJ, Morrissey JH. How it all starts: initiation of the clotting cascade. Crit Rev Biochem Mol Biol. 2015;50(4):326–36.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Neuenschwander PF, Morrissey JH. Roles of the membrane-interactive regions of factor VIIa and tissue factor. The factor VIIa Gla domain is dispensable for binding to tissue factor but important for activation of factor X. J Biol Chem. 1994;269(11):8007–13.PubMedGoogle Scholar
  12. 12.
    Tavoosi N, Smith SA, Davis-Harrison RL, Morrissey JH. Factor VII and protein C are phosphatidic acid-binding proteins. Biochemistry. 2013;52(33):5545–52.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Fair DS. Quantitation of factor VII in the plasma of normal and warfarin-treated individuals by radioimmunoassay. Blood. 1983;62(4):784–91.PubMedGoogle Scholar
  14. 14.
    Vadivel K, Bajaj SP. Structural biology of factor VIIa/tissue factor initiated coagulation. Front Biosci. 2012;17:2476.CrossRefPubMedCentralGoogle Scholar
  15. 15.
    Eigenbrot C, Kirchhofer D, Dennis MS, Santell L, Lazarus RA, Stamos J, et al. The factor VII zymogen structure reveals reregistration of β strands during activation. Structure. 2001;9(7):627–36.CrossRefPubMedGoogle Scholar
  16. 16.
    O’Hara PJ, Grant FJ, Haldeman BA, Gray CL, Insley MY, Hagen FS, et al. Nucleotide sequence of the gene coding for human factor VII, a vitamin K-dependent protein participating in blood coagulation. Proc Natl Acad Sci. 1987;84(15):5158–62.CrossRefPubMedGoogle Scholar
  17. 17.
    Banner DW, D’arcy A, Chene C, Winkler FK, Guha A, Konigsberg WH, et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature. 1996;380(6569):41–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Butenas S, Mann KG. Kinetics of human factor VII activation. Biochemistry. 1996;35(6):1904–10.CrossRefPubMedGoogle Scholar
  19. 19.
    McVey JH, Boswell E, Mumford AD, Kemball‐Cook G, Tuddenham EG. Factor VII deficiency and the FVII mutation database. Hum Mutat. 2001;17(1):3–17.CrossRefPubMedGoogle Scholar
  20. 20.
    Spiezia L, Campello E, Dalla Valle F, Woodhams B, Simioni P. Factor VIIa-antithrombin complex: a possible new biomarker for activated coagulation. Clin Chem Lab Med. 2017;55(4):484–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Rao L, Nordfang O, Hoang A, Pendurthi U. Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity. Blood. 1995;85(1):121–9.PubMedGoogle Scholar
  22. 22.
    Monroe DM, Key N. The tissue factor–factor VIIa complex: procoagulant activity, regulation, and multitasking. J Thromb Haemost. 2007;5(6):1097–105.CrossRefPubMedGoogle Scholar
  23. 23.
    Iakhiaev A, Pendurthi UR, Voigt J, Ezban M, Rao LVM. Catabolism of factor VIIa bound to tissue factor in fibroblasts in the presence and absence of tissue factor pathway inhibitor. J Biol Chem. 1999;274(52):36995–7003.CrossRefPubMedGoogle Scholar
  24. 24.
    Lwaleed BA, Bass PS. Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol. 2006;208(3):327–39.CrossRefPubMedGoogle Scholar
  25. 25.
    Rosen ED, Xu H, Liang Z, Martin JA, Suckow M, Castellino FJ. Generation of genetically-altered mice producing very low levels of coagulation factor VII. Thromb Haemost. 2005;94(3):493–7.PubMedGoogle Scholar
  26. 26.
    Tuddenham EGD, Pemberton S, Cooper DN. Inherited factor VII deficiency: genetics and molecular pathology article in thrombosis and haemostasis. Thromb Haemost. 1995;74(1):313–21.PubMedGoogle Scholar
  27. 27.
    Mariani G, Bernardi F. Factor VII deficiency. Semin Thromb Hemost. 2009;35:400.CrossRefPubMedGoogle Scholar
  28. 28.
    Versteeg HH, Peppelenbosch MP, Spek CA. Tissue factor signal transduction in angiogenesis. Carcinogenesis. 2003;24(6):1009–13.CrossRefPubMedGoogle Scholar
  29. 29.
    Krikun G, Schatz F, Taylor H, Lockwood CJ. Endometriosis and tissue factor. Ann N Y Acad Sci. 2008;1127(1):101–5.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Alexander B, Goldstein R, Landwehr G, Cook C, Addelson E, Wilson C. Congenital SPCA deficiency: a hitherto unrecognized coagulation defect with hemorrhage rectified by serum and serum fractions. J Clin Invest. 1951;30(6):596.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Triplett DA, Brandt JT, Batard M, Dixon J, Fair DS. Hereditary factor VII deficiency: heterogeneity defined by combined functional and immunochemical analysis. Blood. 1985;66(6):1284–7.PubMedGoogle Scholar
  32. 32.
    Girolami A, Santarossa C, Cosi E, Ferrari S, Lombardi AM. Acquired isolated FVII deficiency: an underestimated and potentially important laboratory finding. Clin Appl Thromb Hemost. 2016;22(8):705–11.CrossRefPubMedGoogle Scholar
  33. 33.
    Mulliez SM, Devreese KM. Isolated acquired factor VII deficiency: review of the literature. Acta Clin Belg. 2016;71(2):63–70.PubMedGoogle Scholar
  34. 34.
    Toor A, Slungaard A, Hedner U, Weisdorf D, Key N. Acquired factor VII deficiency in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2002;29(5):403.CrossRefPubMedGoogle Scholar
  35. 35.
    Biron C, Bengler C, Gris J, Schved J. Acquired isolated factor VII deficiency during sepsis. Pathophysiol Haemost Thromb. 1997;27(2):51–6.CrossRefGoogle Scholar
  36. 36.
    Delmer A, Horellou M, Andreu G, Lecompte T, Rossi F, Kazatchkine M, et al. Life-threatening intracranial bleeding associated with the presence of an antifactor VII autoantibody. Blood. 1989;74(1):229–32.PubMedGoogle Scholar
  37. 37.
    Napolitano M, Giansily-Blaizot M, Dolce A, Schved JF, Auerswald G, Ingerslev J, et al. Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER). Haematologica. 2013;98(4):538–44.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Napolitano M, Siragusa S, Mariani G. Factor VII deficiency: clinical phenotype, genotype and therapy. J Clin Med. 2017;6(4):38.CrossRefPubMedCentralGoogle Scholar
  39. 39.
    Mariani G, Mazzucconi M. Factor VII congenital deficiency. Pathophysiol Haemost Thromb. 1983;13(3):169–77.CrossRefGoogle Scholar
  40. 40.
    Peyvandi F, Mannucci P, Asti D, Abdoullahi M, Di Rocco N, Sharifian R. Clinical manifestations in 28 Italian and Iranian patients with severe factor VII deficiency. Haemophilia. 1997;3(4):242–6.CrossRefPubMedGoogle Scholar
  41. 41.
    Giansily-Blaizot M, Verdier R, Biron-Adreani C, Schved J-F, Bertrand M, Borg J, et al. Analysis of biological phenotypes from 42 patients with inherited factor VII deficiency: can biological tests predict the bleeding risk? Haematologica. 2004;89(6):704–9.PubMedGoogle Scholar
  42. 42.
    Mariani G, Herrmann F, Schulman S, Batorova A, Wulff K, Etro D, et al. Thrombosis in inherited factor VII deficiency. J Thromb Haemost. 2003;1(10):2153–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Marty S, Barro C, Chatelain B, Fimbel B, Tribout B, Reynaud J, et al. The paradoxical association between inherited factor VII deficiency and venous thrombosis. Haemophilia. 2008;14(3):564–70.CrossRefPubMedGoogle Scholar
  44. 44.
    Poggio M, Tripodi A, Mariani G, Mannucci PM. Factor VII clotting assay: influence of different thromboplastins and factor VII-deficient plasmas. CISMEL Study Group. Thromb Haemost. 1991;65(2):160–4.CrossRefPubMedGoogle Scholar
  45. 45.
    Takamiya O, Ishikawa S, Ohnuma O, Suehisa H, Iijima K, Kayamori Y, et al. Japanese collaborative study to assess inter‐laboratory variation in factor VII activity assays. J Thromb Haemost. 2007;5(8):1686–92.CrossRefPubMedGoogle Scholar
  46. 46.
    Bleavins MR, Carini C, Jurima-Romet M, Rahbari R. Biomarkers in drug development: a handbook of practice, application, and strategy. Hoboken: Wiley; 2011.Google Scholar
  47. 47.
    Girolami A, Fabris F, Dal Bo ZR, Ghiotto G, Burul A. Factor VII Padua: a congenital coagulation disorder due to an abnormal factor VII with a peculiar activation pattern. J Lab Clin Med. 1978;91(3):387–95.PubMedGoogle Scholar
  48. 48.
    Clinical and Laboratory Standard Institute. Determination of coagulation factor activities using the one-stage clotting assay. Wayne: Clinical and Laboratory Institute; 2016.Google Scholar
  49. 49.
    Smith S, Comp P, Morrissey J. Traces of factor VIIa modulate thromboplastin sensitivity to factors V, VII, X, and prothrombin. J Thromb Haemost. 2006;4(7):1553–8.CrossRefPubMedGoogle Scholar
  50. 50.
    Simpson H, Meade T, Stirling Y, Mann J, Chakrabarti R, Woolf L. Hypertriglyceridaemia and hypercoagulability. Lancet. 1983;321(8328):786–90.CrossRefGoogle Scholar
  51. 51.
    Cid A, Lorenzo J, Haya S, Montoro J, Casana P, Aznar J. A comparison of FVII: C and FVIIa assays for the monitoring of recombinant factor VIIa treatment. Haemophilia. 2001;7(1):39–41.CrossRefPubMedGoogle Scholar
  52. 52.
    Friederich PW, Henny CP, Messelink EJ, Geerdink MG, Keller T, Kurth K-H, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet. 2003;361(9353):201–5.CrossRefPubMedGoogle Scholar
  53. 53.
    Neuenschwander PF, Morrissey JH. Deletion of the membrane anchoring region of tissue factor abolishes autoactivation of factor VII but not cofactor function. Analysis of a mutant with a selective deficiency in activity. J Biol Chem. 1992;267(20):14477–82.PubMedGoogle Scholar
  54. 54.
    Morrissey JH, Macik BG, Neuenschwander PF. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood. 1993;81(3):734–44.PubMedGoogle Scholar
  55. 55.
    Philippou H, Adami A, Amersey RA, Stubbs PJ, Lane DA. A novel specific immunoassay for plasma two-chain factor VIIa: investigation of FVIIa levels in normal individuals and in patients with acute coronary syndromes. Blood. 1997;89(3):767–75.PubMedGoogle Scholar
  56. 56.
    Colman RW. Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia: Lippincott Williams & Wilkins; 2006.Google Scholar
  57. 57.
    Peyvandi F, Garagiola I, Palla R, Marziliano N, Mannucci P. Role of the 2 adenine (g. 11293_11294insAA) insertion polymorphism in the 3’ untranslated region of the factor VII (FVII) gene: molecular characterization of a patient with severe FVII deficiency. Hum Mutat. 2005;26(5):455–61.CrossRefPubMedGoogle Scholar
  58. 58.
    van’t Hooft FM, Silveira A, Tornvall P, Iliadou A, Ehrenborg E, Eriksson P, et al. Two common functional polymorphisms in the promoter region of the coagulation factor VII gene determining plasma factor VII activity and mass concentration. Blood. 1999;93(10):3432–41.Google Scholar
  59. 59.
    Marchetti G, Patracchini P, Papacchini M, Ferrati M, Bernardi F. A polymorphism in the 5’ region of coagulation factor VII gene (F7) caused by an inserted decanucleotide. Hum Genet. 1993;90(5):575–6.Google Scholar
  60. 60.
    Peyvandi F, Mannucci P, Bucciarelli P, Zeinali S, Akhavan S, Sacchi E, et al. A novel polymorphism in intron 1a of the human factor VII gene (G73A): study of a healthy Italian population and of 190 young survivors of myocardial infarction. Br J Haematol. 2000;108(2):247–53.CrossRefPubMedGoogle Scholar
  61. 61.
    Marchetti G, Ferrati M, Patracchini P, Redaelli R, Bernardi F. A missense mutation (178Cys-> Tyr) and two neutral dimorphisms (115His and 333Ser) in the human coagulation factor VII gene. Hum Mol Genet. 1993;2(7):1055–6.CrossRefPubMedGoogle Scholar
  62. 62.
    Marchetti G, Patracchini P, Gemmati D, DeRosa V, Pinotti M, Rodorigo G, et al. Detection of two missense mutations and characterization of a repeat polymorphism in the factor VII gene (F7). Hum Genet. 1992;89(5):497–502.CrossRefPubMedGoogle Scholar
  63. 63.
    Tamary H, Fromovich Y, Shalmon L, Reich Z, Dym O, Lanir N, et al. Ala244Val is a common, probably ancient mutation causing factor VII deficiency in Moroccan and Iranian Jews. Thromb Haemost. 1996;76:283.CrossRefPubMedGoogle Scholar
  64. 64.
    Green F, Kelleher C, Wilkes H, Temple A, Meade T, Humphries S. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb Vasc Biol. 1991;11(3):540–6.CrossRefGoogle Scholar
  65. 65.
    Tabibian S, Shams M, Naderi M, Dorgalaleh A. Prenatal diagnosis in rare bleeding disorders-An unresolved issue? Int J Lab Hematol. 2018.  https://doi.org/10.1111/ijlh.12789.
  66. 66.
    Peyvandi F, Menegatti M. Treatment of rare factor deficiencies in 2016. Hematology Am Soc Hematol Educ Program. 2016;2016(1):663–9.PubMedGoogle Scholar
  67. 67.
    Asif M, Siddiqui A, Scott LJ. Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders. Drugs. 2005;65(8):1161–78.CrossRefGoogle Scholar
  68. 68.
    Croom KF, McCormack PL. Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders. BioDrugs. 2008;22(2):121–36.CrossRefPubMedGoogle Scholar
  69. 69.
    Hedner U, Glazer S, Pingel K, Alberts KA, Blonback M, Schulman S, et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet. 1988;332:1193.CrossRefGoogle Scholar
  70. 70.
    Sadeghi N, Kahn D, Syed D, Iqbal O, Abro S, Eshraghi R, et al. Comparative biochemical and functional studies on a branded human recombinant factor VIIa and a biosimilar equivalent product. Clin Appl Thromb Hemost. 2014;20(6):565–72.CrossRefPubMedGoogle Scholar
  71. 71.
    Faranoush M, Abolghasemi H, Toogeh G, Karimi M, Eshghi P, Managhchi M, et al. A comparison between recombinant activated factor VII (Aryoseven) and Novoseven in patients with congenital factor VII deficiency. Clin Appl Thromb Hemost. 2015;21(8):724–8.CrossRefPubMedGoogle Scholar
  72. 72.
    Faranoush M, Abolghasemi H, Mahboudi F, Toogeh G, Karimi M, Eshghi P, et al. A comparison of efficacy between recombinant activated factor VII (Aryoseven) and Novoseven in patients with hereditary FVIII deficiency with inhibitor. Clin Appl Thromb Hemost. 2016;22(2):184–90.CrossRefPubMedGoogle Scholar
  73. 73.
    Miller RD, Eriksson LI, Fleisher LA, Wiener-Kronish JP, Cohen NH, Young WL. Miller’s anesthesia. London: Elsevier Health Sciences; 2014.Google Scholar
  74. 74.
    Bauer KA. Treatment of factor VII deficiency with recombinant factor VIla. Pathophysiol Haemost Thromb. 1996;26(Suppl. 1):155–8.CrossRefGoogle Scholar
  75. 75.
    CSL Behring. Beriplex® P/N 250, 500 and 1000 IU [package leaflet]. CSL Behring GmbH, Marburg. 2014.Google Scholar
  76. 76.
    CSL Behring. KCENTRA (Prothrombin complex concentrate (human), [package insert]. CSL Behring GmbH, Marburg. 2013.Google Scholar
  77. 77.
    Sanquin. Cofact 250, 500 IU [information for use]. Sanquin Plasma Products B.V., Amsterdam. 2016.Google Scholar
  78. 78.
    LFB-BIOMEDICAMENTS. KASKADIL (human coagulation factor II) [patient information leaflet]. Courtaboeuf Cedex. 2010.Google Scholar
  79. 79.
    Octapharma. Octaplex 500, 1000. [package leaflet]. Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna. 2015.Google Scholar
  80. 80.
    Baxalta. Prothromplex TOTAL 600 IU [package leaflet]. Baxalta Innovations GmbH, Vienna. 2015.Google Scholar
  81. 81.
    Baxter. Proplex-T (factor IX complex). Baxter Healthcare Corporation, Glendale. 2000.Google Scholar
  82. 82.
    Awad NI, Cocchio C. Activated prothrombin complex concentrates for the reversal of anticoagulant-associated coagulopathy. Pharm Ther. 2013;38(11):696.Google Scholar
  83. 83.
    Sørensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R. Clinical review: prothrombin complex concentrates-evaluation of safety and thrombogenicity. Crit Care. 2011;15(1):201.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Dentali F, Marchesi C, Pierfranceschi MG, Crowther M, Garcia D, Hylek E, et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. Thromb Haemost. 2011;106(3):429–38.PubMedGoogle Scholar
  85. 85.
    Grottke O, Rossaint R, Henskens Y, van Oerle R, ten Cate H, Spronk HM. Thrombin generation capacity of prothrombin complex concentrate in an in vitro dilutional model. PLoS One. 2013;8(5):e64100.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H. Prothrombin complex concentrate (Beriplex® P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 2008;6(4):622–31.CrossRefPubMedGoogle Scholar
  87. 87.
    Schulman S, Bijsterveld NR. Anticoagulants and their reversal. Transfus Med Rev. 2007;21(1):37–48.CrossRefPubMedGoogle Scholar
  88. 88.
    Strengers P, Drenth J. PPSB as first choice treatment in the reversal of oral anticoagulant therapy. Acta Anaesthesiol Belg. 2001;53(3):183–6.Google Scholar
  89. 89.
    Lusher J. Thrombogenicity associated with factor IX complex concentrates. Semin Hematol. 1991;28:3.PubMedGoogle Scholar
  90. 90.
    Schulman S, Johnsson H, Lindmarker P. Thrombotic complications after substitution with a FVII concentrate. Thromb Haemost. 1991;66(5):619.PubMedCrossRefGoogle Scholar
  91. 91.
    Escoffre M, Zini J, Schuamser L, Mazoyer E, Soria C, Tobelem G, et al. Severe arterial thrombosis in a congenitally factor VII deficient patient. Br J Haematol. 1995;91(3):739–41.CrossRefPubMedGoogle Scholar
  92. 92.
    Ferster A, Capouet V, Deville A, Fondu P, Corazza F. Cardiac surgery with extracorporeal circulation in severe factor VII deficiency. Pathophysiol Haemost Thromb. 1993;23(1):65–8.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Mahmood Shams
    • 1
    • 2
  • Akbar Dorgalaleh
    • 2
  1. 1.Department of Laboratory Sciences, Paramedical FacultyBabol University of Medical SciencesBabolIran
  2. 2.Department of Hematology and Blood transfusion, School of Allied MedicineIran University of Medical SciencesTehranIran

Personalised recommendations

Cite chapter

Buy options